Christopher Richard Anzalone Sells 133,333 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the completion of the transaction, the chief executive officer now directly owns 3,773,802 shares of the company’s stock, valued at $64,230,110.04. The trade was a 3.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

• On Thursday, January 2nd, Christopher Richard Anzalone sold 11,520 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $19.05, for a total transaction of $219,456.00.
• On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.59, for a total transaction of $246,109.17.
• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $16.97 on Friday. The company’s fifty day moving average price is $19.43 and its 200 day moving average price is $20.58. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $16.57 and a 12 month high of $35.47. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The firm has a market capitalization of $2.14 billion, a P/E ratio of -3.28 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). As a group, sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ARWR. R Squared Ltd acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at $38,000. GF Fund Management CO. LTD. acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $49,000. Van ECK Associates Corp boosted its holdings in Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ARWR has been the subject of several research reports. Sanford C. Bernstein dropped their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. B. Riley restated a “buy” rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.